Proteome Regulatory News (PRM)

18 Jul 2006 07:00

PROTEOME SCIENCES plc PRESS RELEASE For immediate release 18th July, 2006 PROTEOME SCIENCES APPOINTS CHIEF SCIENTIFIC OFFICER Proteome Sciences plc ("Proteome Sciences" or "the Company") is pleased toannounce that Dr. Peter Schulz-Knappe will join the Company on 1st August, 2006as Research and Development Director/CSO. Dr. Schulz-Knappe will be splittinghis responsibilities between the Company's Head Office in Cobham and itslaboratories in Frankfurt and London.Prior to its takeover by Digilab LLC in February 2006, Dr. Schulz-Knappe wasCSO and founder of BioVision GmbH ("BioVision"), a company that has used massspectrometry to quantify and sequence biomarkers in pharmacogenomics andpersonalised medicine through differential peptide display (peptidomics).Formally Head of the Department at the Lower Saxony Institute of PeptideChemistry, Dr. Schulz-Knappe worked in cell biology and peptide and proteinrelated science for 20 years and established a large network within the pharma,diagnostics and biotech industries. These have included strategic researchalliances with many majors including Abbott, Novartis, Novo Nordisk, AstraZeneca and Roche.Commenting on the appointment of Dr. Schulz-Knappe, Christopher Pearce, ChiefExecutive of Proteome Sciences said:"We are delighted that Dr. Schulz-Knappe will be joining us at this excitingstage of our development. Having recently entered into licences for our strokebiomarkers with two of the top ten global clinical diagnostic companies in highthroughput screening, we are keen to expand the coverage to the other mainplayers and to conclude similar agreements from our burgeoning portfolio ofbiomarkers in neurodegenerative disorders, cancer and kidney transplantrejection.The recent signals from the US FDA of its intention to widen the scope ofbiomarker data for new drug applications is a significant and positive shiftwhich should accelerate the pace of completion of other external licences andfurther increase confidence in our future prospects."Notes to editors:Proteome Sciences plcProteome Sciences, a global leader in applied proteomics, uses high sensitivityproprietary technologies to detect differentially expressed proteins indiseases. The protein biomarkers discovered in body fluids or tissues arevalidated, developed and commercialised as diagnostic, prognostic ortherapeutic products through strategic alliances and out-licensing.Through its unique ProteoSHOP‚® toolbox, Proteome Sciences provides highsensitivity/high throughput proteomics solutions, including traditional twodimensional gel-based electrophoresis (2DE) and proprietary gel-free proteinsequence tag technologies (PST‚®, qPST¢â€ž¢& TMT‚®), to major pharma, biotechnologyand diagnostic companies, to discover and exploit protein biomarkers.Sensitizer‚® chemical mass tags have been developed separately as a series ofstand-alone reagents.For further information please visit www.proteomics.com .Enquiries:Proteome Sciences plcChristopher Pearce, Chief Executive OfficerEmail: christopher.pearce@proteomics.comTel: +44 (0)1932 865065Public Relations for Proteome SciencesIKON AssociatesAdrian ShawTel: +44 (0)1483 535102Mobile: +44 (0)797 9900733Email: adrian@ikonassociates.comENDPROTEOME SCIENCES PLC